predictive oncology (nasdaq: poai) is focused on the use of data and artificial intelligence (ai) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcome. the company has several tools that support its mission of bringing precision medicine to the diagnosis of cancer. through its subsidiaries, predictive oncology’s portfolio of assets includes the following: - a database of clinically validated historical and outcome data from patient tumors - an in-house clinical laboratory improvement amendments (clia)-certified lab - a “smart” patient-derived tumor profiling platform - an in-house bioinformatics artificial intelligence (ai) platform - a new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options - an fda-approved fluid collection and disposal system using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries
![Predictive Oncology logo](https://files.capedge.com/S-1/0001171843-20-004383/logo.jpg)
Company profile
Ticker
POAI
Exchange
Website
CEO
Carl Schwartz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
BioDrain Medical, Inc., Precision Therapeutics Inc., Skyline Medical Inc.
SEC CIK
Corporate docs
Subsidiaries
Helomics Corporation • Skyline Medical, Inc. ...
IRS number
331007393
POAI stock data
Latest filings (excl ownership)
8-K
Other Events
30 May 24
EFFECT
Notice of effectiveness
22 May 24
S-3/A
Shelf registration (amended)
21 May 24
8-K
Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update
15 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Entry into a Material Definitive Agreement
3 May 24
8-K
Changes in Registrant's Certifying Accountant
8 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
28 Mar 24
8-K/A
Submission of Matters to a Vote of Security Holders
22 Mar 24
Transcripts
POAI
Earnings call transcript
2024 Q1
15 May 24
POAI
Earnings call transcript
2023 Q4
1 Apr 24
POAI
Earnings call transcript
2023 Q3
14 Nov 23
POAI
Earnings call transcript
2023 Q2
10 Aug 23
POAI
Earnings call transcript
2023 Q2
10 Aug 23
POAI
Earnings call transcript
2023 Q1
15 May 23
POAI
Earnings call transcript
2022 Q4
22 Mar 23
POAI
Earnings call transcript
2022 Q3
11 Nov 22
POAI
Earnings call transcript
2022 Q2
12 Aug 22
POAI
Earnings call transcript
2019 Q2
19 Aug 19
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.20 mm | 5.20 mm | 5.20 mm | 5.20 mm | 5.20 mm | 5.20 mm |
Cash burn (monthly) | 1.18 mm | 1.12 mm | 1.41 mm | 1.24 mm | 1.14 mm | 1.10 mm |
Cash used (since last report) | 3.23 mm | 3.07 mm | 3.88 mm | 3.40 mm | 3.13 mm | 3.02 mm |
Cash remaining | 1.96 mm | 2.13 mm | 1.32 mm | 1.80 mm | 2.07 mm | 2.18 mm |
Runway (months of cash) | 1.7 | 1.9 | 0.9 | 1.5 | 1.8 | 2.0 |
Institutional ownership, Q3 2023
9.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 4 |
Closed positions | 0 |
Increased positions | 3 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 1.13 bn |
Total shares | 368.70 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 140.60 k | $449.93 mm |
Raymond James & Associates | 118.23 k | $378.33 mm |
Geode Capital Management | 37.47 k | $119.94 mm |
RB Capital Management | 20.84 k | $66.67 mm |
Renaissance Technologies | 16.88 k | $54.00 k |
STT State Street | 16.84 k | $53.88 mm |
Susquehanna International | 12.27 k | $39.25 mm |
UBS UBS Group AG - Registered Shares | 2.47 k | $7.90 mm |
Advisor | 1.53 k | $4.88 mm |
Tower Research Capital | 694.00 | $2.22 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Nancy Chung-welch | Common Stock | Grant | Acquire A | No | No | 0 | 2,353 | 0.00 | 21,237 |
5 Apr 24 | Matthew Hawryluk | Common Stock | Grant | Acquire A | No | No | 0 | 2,368 | 0.00 | 9,488 |
5 Apr 24 | Veena Rao | Common Stock | Grant | Acquire A | No | No | 0 | 3,268 | 0.00 | 9,117 |
5 Apr 24 | Charles Lee Nuzum Sr | Common Stock | Grant | Acquire A | No | No | 0 | 3,268 | 0.00 | 31,921 |
5 Apr 24 | Handley Daniel E | Common Stock | Grant | Acquire A | No | No | 0 | 2,353 | 0.00 | 18,661 |
News
Predictive Oncology Introduces New Technology For Expressing Functional And Stable G-Protein Coupled Receptors (GPCRs)
11 Jun 24
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
29 May 24
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
29 May 24
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
28 May 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
28 May 24
Press releases
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
4 Jun 24
Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
29 May 24
Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update
15 May 24
Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024
10 May 24
Fujifilm and Predictive Oncology Announce Collaboration to Reduce Protein Interference in Bacterial Endotoxin Detection Testing of Biopharmaceuticals
25 Apr 24